Cargando…
The Challenge of Sustainability of High-Cost Oncological Drugs: A Budgeting Model in an Italian Cancer Center
In Italy, drug expenditure governance is achieved by setting caps based on the percentage increase in hospital spending compared to the previous year. This method is ineffective in identifying issues and opportunities as it does not consider an analysis of the number of treated cases and per capita...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8707715/ https://www.ncbi.nlm.nih.gov/pubmed/34949032 http://dx.doi.org/10.3390/ijerph182413413 |
_version_ | 1784622503872692224 |
---|---|
author | Masini, Carla Gallegati, Davide Gentili, Nicola Massa, Ilaria Ciucci, Raffaella Altini, Mattia |
author_facet | Masini, Carla Gallegati, Davide Gentili, Nicola Massa, Ilaria Ciucci, Raffaella Altini, Mattia |
author_sort | Masini, Carla |
collection | PubMed |
description | In Italy, drug expenditure governance is achieved by setting caps based on the percentage increase in hospital spending compared to the previous year. This method is ineffective in identifying issues and opportunities as it does not consider an analysis of the number of treated cases and per capita consumption in local and regional settings. The IRCCS (Scientific hospitalization and treatment institute) Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori” in Meldola, has developed and adopted an effective management model designed to oversee pharmaceutical expenditure, guarantee prescription appropriateness and quality of care to patients. The budget setting follows a structured process which evaluates determining factors of the expenditure such as expected patients calculated according to the epidemiology and to national and regional indications of appropriateness, mean cost per patient calculated on the average period of demonstrated efficacy of the drug and use of drugs with the best cost-effectiveness ratio. Strict monitoring and integrated purchasing processes allow for immediate corrective actions on expenditures, as well as a continuous dialogue with the region in order to guarantee consistent funding of IRST activities. The model, presented in this article is efficient and implements concepts beyond the conventional “silos” approach and national and regional governance tools, in terms of patient centricity. |
format | Online Article Text |
id | pubmed-8707715 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-87077152021-12-25 The Challenge of Sustainability of High-Cost Oncological Drugs: A Budgeting Model in an Italian Cancer Center Masini, Carla Gallegati, Davide Gentili, Nicola Massa, Ilaria Ciucci, Raffaella Altini, Mattia Int J Environ Res Public Health Article In Italy, drug expenditure governance is achieved by setting caps based on the percentage increase in hospital spending compared to the previous year. This method is ineffective in identifying issues and opportunities as it does not consider an analysis of the number of treated cases and per capita consumption in local and regional settings. The IRCCS (Scientific hospitalization and treatment institute) Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori” in Meldola, has developed and adopted an effective management model designed to oversee pharmaceutical expenditure, guarantee prescription appropriateness and quality of care to patients. The budget setting follows a structured process which evaluates determining factors of the expenditure such as expected patients calculated according to the epidemiology and to national and regional indications of appropriateness, mean cost per patient calculated on the average period of demonstrated efficacy of the drug and use of drugs with the best cost-effectiveness ratio. Strict monitoring and integrated purchasing processes allow for immediate corrective actions on expenditures, as well as a continuous dialogue with the region in order to guarantee consistent funding of IRST activities. The model, presented in this article is efficient and implements concepts beyond the conventional “silos” approach and national and regional governance tools, in terms of patient centricity. MDPI 2021-12-20 /pmc/articles/PMC8707715/ /pubmed/34949032 http://dx.doi.org/10.3390/ijerph182413413 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Masini, Carla Gallegati, Davide Gentili, Nicola Massa, Ilaria Ciucci, Raffaella Altini, Mattia The Challenge of Sustainability of High-Cost Oncological Drugs: A Budgeting Model in an Italian Cancer Center |
title | The Challenge of Sustainability of High-Cost Oncological Drugs: A Budgeting Model in an Italian Cancer Center |
title_full | The Challenge of Sustainability of High-Cost Oncological Drugs: A Budgeting Model in an Italian Cancer Center |
title_fullStr | The Challenge of Sustainability of High-Cost Oncological Drugs: A Budgeting Model in an Italian Cancer Center |
title_full_unstemmed | The Challenge of Sustainability of High-Cost Oncological Drugs: A Budgeting Model in an Italian Cancer Center |
title_short | The Challenge of Sustainability of High-Cost Oncological Drugs: A Budgeting Model in an Italian Cancer Center |
title_sort | challenge of sustainability of high-cost oncological drugs: a budgeting model in an italian cancer center |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8707715/ https://www.ncbi.nlm.nih.gov/pubmed/34949032 http://dx.doi.org/10.3390/ijerph182413413 |
work_keys_str_mv | AT masinicarla thechallengeofsustainabilityofhighcostoncologicaldrugsabudgetingmodelinanitaliancancercenter AT gallegatidavide thechallengeofsustainabilityofhighcostoncologicaldrugsabudgetingmodelinanitaliancancercenter AT gentilinicola thechallengeofsustainabilityofhighcostoncologicaldrugsabudgetingmodelinanitaliancancercenter AT massailaria thechallengeofsustainabilityofhighcostoncologicaldrugsabudgetingmodelinanitaliancancercenter AT ciucciraffaella thechallengeofsustainabilityofhighcostoncologicaldrugsabudgetingmodelinanitaliancancercenter AT altinimattia thechallengeofsustainabilityofhighcostoncologicaldrugsabudgetingmodelinanitaliancancercenter AT masinicarla challengeofsustainabilityofhighcostoncologicaldrugsabudgetingmodelinanitaliancancercenter AT gallegatidavide challengeofsustainabilityofhighcostoncologicaldrugsabudgetingmodelinanitaliancancercenter AT gentilinicola challengeofsustainabilityofhighcostoncologicaldrugsabudgetingmodelinanitaliancancercenter AT massailaria challengeofsustainabilityofhighcostoncologicaldrugsabudgetingmodelinanitaliancancercenter AT ciucciraffaella challengeofsustainabilityofhighcostoncologicaldrugsabudgetingmodelinanitaliancancercenter AT altinimattia challengeofsustainabilityofhighcostoncologicaldrugsabudgetingmodelinanitaliancancercenter |